MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2023.107453

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2023

Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.

Kitagawa Shingo, Zenke Yoshitaka, Taki Tetsuro, Aokage Keiju, Sakai Tetsuya, Shibata Yuji, Izumi Hiroki, Nosaki Kaname, Umemura Shigeki, Matsumoto Shingo, Yoh Kiyotaka, Sakamoto Naoya, Sakashita Shingo, Kojima Motohiro, Tsuboi Masahiro, Goto Koichi, Ishii Genichiro

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

This study extracted clinicopathological features associated with recurrence and evaluated the tumor microenvironment in consecutive cases with resected pathological stage II-III epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (EGFR-mt).

METHODS

Between January 2008 and November 2018, we retrospectively reviewed 387 consecutive patients with pathological stage II-III lung adenocarcinoma who underwent surgical resection. We examined the EGFR mutation status (wild-type or mutant) and the evaluated clinicopathological features of all patients. In addition, tumor-promoting cancer-associated fibroblasts (CAFs), tumor-associated M2 macrophages (TAMs), and tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment of EGFR-mt cells were evaluated by immunohistochemical analysis.

RESULTS

EGFR-mt (n = 124, 32 %) had more lymph node and pulmonary metastases than EGFR-wild-type lung adenocarcinoma (EGFR-wt) despite the smaller invasive component size. The disease-free survival (DFS) of patients with EGFR-mt tended to be shorter than that of patients with EGFR-wt. In the analysis according to the predominant subtype, EGFR-mt with papillary-predominant subtype had a significantly shorter 5-year DFS than that of EGFR-wt with papillary-predominant subtype (15.3 % vs. 44.1 %, p < 0.01). We observed no significant differences among the other subtypes. Multivariate analysis of DFS in patients with EGFR-mt revealed that male sex, pathological stage III, lymph node metastasis, pulmonary metastasis in the same lobe and non-acinar and non-lepidic predominant subtypes (papillary, solid, or micropapillary) were independent poor prognostic factors. Immunohistochemical analysis of EGFR-mt revealed that non-acinar- and non-lepidic-predominant subtypes were associated with a higher frequency of podoplanin-positive CAFs (36 % vs. 13 %, p = 0.01) and a higher median number of CD204-positive TAMs (61 vs. 49, p = 0.07) compared to the acinar- or lepidic-predominant subtypes.

CONCLUSIONS

Non-acinar and non-lepidic predominant subtypes were predictors of recurrence and had an aggressive tumor microenvironment in pathological stage II-III EGFR-mt.

Для цитирования: Kitagawa Shingo, Zenke Yoshitaka, Taki Tetsuro, Aokage Keiju, Sakai Tetsuya, Shibata Yuji, Izumi Hiroki, Nosaki Kaname, Umemura Shigeki, Matsumoto Shingo, Yoh Kiyotaka, Sakamoto Naoya, Sakashita Shingo, Kojima Motohiro, Tsuboi Masahiro, Goto Koichi, Ishii Genichiro. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.. Lung cancer (Amsterdam, Netherlands). 2023. DOI: 10.1016/j.lungcan.2023.107453.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.